CureVac N.V. — Regulatory Filings 2020

Nov 2, 2020

6-K 1 tm2034712d1_6k.htm FORM 6-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

Form 6-K

Field: Rule-Page

Field: /Rule-Page

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2020

Commission File Number 001-39446

Field: Rule-Page

Field: /Rule-Page

CureVac N.V.

Field: Rule-Page

Field: /Rule-Page

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive offices)

Field: Rule-Page

Field: /Rule-Page

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

FORM 20-F x FORM 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

YES ¨ NO x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

On November 2, 2020, CureVac N.V. (the “Company”) issued a press release reporting interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV. The press release is attached hereto as Exhibit 99.1.

The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By:	/s/ Franz-Werner Haas, LLD, LLM
	Chief Executive Officer

Date: November 2, 2020

Field: Page; Sequence: 3

Field: /Page

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	CureVac N.V. Press Release dated November 2, 2020.

Field: Page; Sequence: 4; Options: Last

Field: /Page